# A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

> **NCT07121413** · PHASE2 · RECRUITING · sponsor: **Shanghai Synvida Biotechnology Co.,Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis(IPF)

## Interventions

- **DRUG:** SV001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07121413
- **Lead sponsor:** Shanghai Synvida Biotechnology Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07121413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07121413, "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07121413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*